Brian S. Posner
Brian S. Posner's purchase track record
How the stock did after each of Brian S. Posner's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/2/2026 | DYN | $40K | pending | pending | — |
| 6/3/2026 | DYN | $78K | +39.7% | pending | — |
| 5/20/2026 | DYN | $79K | +52.6% | pending | — |
| 3/30/2026 | DYN | $34K | +24.4% | -4.4% | +21.1% |
| 3/6/2026 | DYN | $84K | +14.7% | +63.4% | +14.5% |
| 8/1/2025 | ACGL | $17K | -1.9% | +9.1% | +11.2% |
| 10/28/2022 | ACGL | $35K | +13.0% | +32.5% | +6.9% |
| 4/29/2022 | ACGL | $38K | -2.8% | +24.1% | -5.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Arch Capital Group outpaces market as insurers face earnings season. Arch Capital Group’s shares rose higher than the broader market today, according to Yahoo. The move comes as several insurers, including Chubb, W.R. Berkley and Travelers, are being watched for upcoming earnings results. Analysts note that the broader insurance sector is in focus, which may add attention to ACGL’s performance.
Transaction History
| DYN | ▲ Buy | Open Market | 2,500 | $40K | 10/2/2026 | View on chart |
| DYN | ▲ Buy | Open Market | 2,000 | $34K | 6/8/2026 | View on chart |
| ACGL | ▼ Sell | Open Market | 3,000 | $59K | 6/3/2026 | View on chart |
| DYN | ▲ Buy | Open Market | 2,500 | $44K | 6/3/2026 | View on chart |
| DYN | ▲ Buy | Open Market | 2,000 | $36K | 5/26/2026 | View on chart |
| DYN | ▲ Buy | Open Market | 2,500 | $43K | 5/20/2026 | View on chart |
| ACGL | ▼ Sell | Open Market | 2,000 | $34K | 5/11/2026 | View on chart |
| ACGL | ▲ Buy | Grant | 2,071 | — | 5/5/2026 | View on chart |
| DYN | ▲ Buy | Open Market | 2,000 | $34K | 3/30/2026 | View on chart |
| ACGL | ▼ Sell | Open Market | 3,000 | $51K | 3/11/2026 | View on chart |
| DYN | ▲ Buy | Open Market | 2,000 | $39K | 3/11/2026 | View on chart |
| DYN | ▲ Buy | Open Market | 3,000 | $45K | 3/6/2026 | View on chart |
| ACGL | ▲ Buy | Open Market | 1,000 | $17K | 8/1/2025 | View on chart |
| ACGL | ▲ Buy | Grant | 1,564 | — | 5/7/2025 | View on chart |
| ACGL | ▲ Buy | Grant | 1,455 | — | 5/9/2024 | View on chart |
| ACGL | ▲ Buy | Grant | 1,714 | — | 5/4/2023 | View on chart |
| ACGL | ▲ Buy | Open Market | 2,000 | $35K | 10/28/2022 | View on chart |
| ACGL | ▲ Buy | Grant | 2,642 | — | 5/4/2022 | View on chart |
| ACGL | ▲ Buy | Grant | 2,642 | — | 5/4/2022 | View on chart |
| ACGL | ▲ Buy | Open Market | 2,000 | $38K | 4/29/2022 | View on chart |
| ACGL | ▼ Sell | Other | 2,000 | $50K | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Dyne Therapeutics highlighted in recent healthcare stock coverage
Dyne Therapeutics appeared in a Benzinga pre‑market roundup of 12 health‑care stocks. Yahoo highlighted the company in a piece about why it is back in the spotlight, and Raymond James analysts listed it among four health‑care stocks they back. The coverage brings renewed attention to DYN as it trades near its recent support level.
Dyne Therapeutics highlighted in recent healthcare stock coverage. Dyne Therapeutics appeared in a Benzinga pre‑market roundup of 12 health‑care stocks. Yahoo highlighted the company in a piece about why it is back in the spotlight, and Raymond James analysts listed it among four health‑care stocks they back. The coverage brings renewed attention to DYN as it trades near its recent support level.